Trials / Conditions / Fibrodysplasia Ossificans Progressiva

Fibrodysplasia Ossificans Progressiva

15 registered clinical trials studyying Fibrodysplasia Ossificans Progressiva — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants NCT06089616	Ipsen	—
Active Not Recruiting	A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) NCT06508021	Ashibio Inc	Phase 2 / Phase 3
Active Not Recruiting	A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (I NCT05394116	Regeneron Pharmaceuticals	Phase 3
Active Not Recruiting	A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Tre NCT05039515	Clementia Pharmaceuticals Inc.	Phase 2
Completed	Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects NCT04818398	Daiichi Sankyo Co., Ltd.	Phase 1
Completed	An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) NCT04665323	Ipsen	—
Recruiting	Saracatinib Trial TO Prevent FOP NCT04307953	Amsterdam UMC, location VUmc	Phase 2
Completed	Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on NCT04829773	Clementia Pharmaceuticals Inc.	Phase 1
Completed	A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients Wit NCT03188666	Regeneron Pharmaceuticals	Phase 2
Completed	An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. NCT03312634	Clementia Pharmaceuticals Inc.	Phase 3
Terminated	In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) S NCT02521792	Clementia Pharmaceuticals Inc.	Phase 2
Completed	A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP) NCT02322255	Clementia Pharmaceuticals Inc.	—
Completed	An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) NCT02279095	Clementia Pharmaceuticals Inc.	Phase 2
Completed	An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects NCT02190747	Clementia Pharmaceuticals Inc.	Phase 2
Completed	Urine Sample Collection From FOP Patients NCT02066324	Novartis Pharmaceuticals	—